SueWallSt

#107 $QURE uniQure Gene Therapy Breakthrough or Regulatory Reversal

In this episode of Sue Wall Street Holding Wall Street Accountable, we break down the securities class action involving $QURE uniQure and its AMT 130 gene therapy for Huntington disease. We examine the seventy five percent slowing claim, the Phase One Phase Two trial using an external control from ENROLL HD, the Biologics License Application timeline, the FDA reversal on study alignment, the three hundred forty five million dollar stock offering, and the forty nine percent stock drop. This deep dive is for biotech investors, healthcare traders, and anyone following gene therapy stocks, FDA approvals, clinical trial risk, and securities litigation news.
Visit ZLK.com for more info.
Add our WhatsApp Channel.
We’re not lawyers or accountants, so don’t take this as legal or financial advice.

#106 $KD Kyndryl Controls in Place or Confidence Collapse

In this episode of Sue Wall Street Holding Wall Street Accountable, we break down the securities class action involving $KD Kyndryl and alleged misstatements about internal controls over financial reporting. We examine IT general control weaknesses, cash flow misstatements, the late Form 10 Q filing, SEC Division of Enforcement inquiry, executive departures, and the fifty five percent stock drop that followed. This deep dive is for tech investors, corporate governance watchers, and anyone tracking accounting risk and securities litigation news.
Visit ZLK.com for more info.
Add our WhatsApp Channel.
We’re not lawyers or accountants, so don’t take this as legal or financial advice.

#105 $INO Inovio Fast Track Dream or Regulatory Reality

In this episode of Sue Wall Street Holding Wall Street Accountable, we break down the securities class action involving $INO Inovio Pharmaceuticals and its accelerated approval hopes for INO 3107 and the CELLECTRA device. We examine the Biologics License Application delay, manufacturing issues, FDA standard review decision, stock offerings, and the twenty four percent stock drop that followed. This deep dive is for biotech investors, healthcare traders, and anyone following FDA approvals, DNA medicines, regulatory risk, and securities litigation news.
Visit ZLK.com for more info.
Add our WhatsApp Channel.
We’re not lawyers or accountants, so don’t take this as legal or financial advice.

#104 $PSFE Paysafe Payment Growth or Chargeback Shock

In this episode of Sue Wall Street Holding Wall Street Accountable, we break down the securities class action involving $PSFE Paysafe and alleged undisclosed concentration risk in its ecommerce business. We examine revenue guidance, credit loss reserves, chargebacks tied to a high risk merchant, Merchant Category Code exposure, sponsor bank pressure, and the twenty seven percent stock drop that followed. This deep dive is for retail investors, fintech traders, and anyone tracking payment processing stocks, earnings volatility, and securities litigation news.
Visit ZLK.com for more info.
Add our WhatsApp Channel
We’re not lawyers or accountants, so don’t take this as legal or financial advice.

#103 $TCPC BlackRock TCP Capital Steady NAV or Valuation Shock

In this episode of Sue Wall Street Holding Wall Street Accountable, we break down the securities class action involving $TCPC BlackRock TCP Capital and alleged misstatements about net asset value, portfolio health, and non accrual investments. We examine NAV declines from ten dollars to near seven dollars, rising unrealized losses, restructuring efforts, and the sharp stock drops that followed. This deep dive is for income investors, BDC shareholders, and anyone tracking dividend stocks, credit risk, valuation practices, and securities litigation news.
Visit ZLK.com for more info.
Add our WhatsApp Channel
We’re not lawyers or accountants, so don’t take this as legal or financial advice.

#102 $MREO Mereo BioPharma Stronger Bones or Shattered Expectations

In this episode of Sue Wall Street Holding Wall Street Accountable, we examine the securities class action involving $MREO Mereo BioPharma and its Phase Three ORBIT and COSMIC trials for setrusumab in osteogenesis imperfecta. We break down Phase Two bone mineral density data, missed fracture reduction endpoints, interim analysis results, the eighty seven percent stock collapse, and alleged misleading statements about clinical confidence. This deep dive is for biotech investors, healthcare traders, and anyone following rare disease drug development, clinical trial risk, and securities litigation news.
Visit ZLK.com for more info.
Add our WhatsApp Channel
We’re not lawyers or accountants, so don’t take this as legal or financial advice.

#101 $RARE Ultragenyx Stronger Bones or Broken Thesis

In this episode of Sue Wall Street Holding Wall Street Accountable, we break down the securities class action involving $RARE Ultragenyx and its Phase Three Orbit and Cosmic trials for setrusumab in osteogenesis imperfecta. We examine bone mineral density gains, failed fracture reduction endpoints, interim analysis results, the forty two percent stock drop, and alleged misleading statements about clinical trial confidence. This deep dive is for biotech investors, healthcare traders, and anyone following rare disease drug development, FDA pathways, and securities litigation news.
Visit ZLK.com for more info.
Add our WhatsApp Channel.
We’re not lawyers or accountants, so don’t take this as legal or financial advice.

#100 $ORCL Oracle AI Spending Surge or Revenue Reality Check

In this episode of Sue Wall Street Holding Wall Street Accountable, we examine the securities class action involving $ORCL Oracle and its massive artificial intelligence infrastructure expansion. We break down ballooning capital expenditures from twenty five billion to fifty billion dollars, negative free cash flow, two hundred forty eight billion dollars in lease commitments, insider stock sales, and the sharp stock drops that followed. This deep dive is for retail investors, tech stock traders, and anyone tracking AI investing, cloud computing, corporate governance, and securities litigation news.
Visit ZLK.com for more info.
Add our WhatsApp Channel.
We’re not lawyers or accountants, so don’t take this as legal or financial advice.

#099 $PLUG Plug Power Hydrogen Highway or Funding Freeze

In this episode of Sue Wall Street Holding Wall Street Accountable, we unpack the securities class action involving $PLUG Plug Power and its one billion six hundred sixty million dollar Department of Energy loan guarantee. We break down hydrogen production plans, the Texas facility, capital raises, executive departures, liquidity pivots, and the stock drops that followed. This deep dive is for retail investors, clean energy traders, and anyone following hydrogen stocks, DOE financing, and securities litigation news.
Visit ZLK.com for more info.
Add our WhatsApp Channel.
We’re not lawyers or accountants, so don’t take this as legal or financial advice.

#098 $PMI Picard Medical Artificial Heart or Artificial Hype

In this episode of Sue Wall Street Holding Wall Street Accountable, we examine the securities class action involving $PMI Picard Medical and its low float IPO, extreme stock volatility, and alleged social media stock promotion scheme. We break down the four dollar IPO, the rapid surge above thirteen dollars, the seventy percent collapse, WhatsApp trading groups, micro cap manipulation risks, and Rule 10b5 claims. This deep dive is for retail investors, IPO traders, and anyone following stock market news, pump and dump allegations, and securities litigation.
Visit ZLK.com for more info.
Add our WhatsApp Channel.
We’re not lawyers or accountants, so don’t take this as legal or financial advice.